ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 232 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2021. The put-call ratio across all filers is 8.37 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $780,906 | -38.7% | 19,474 | -8.8% | 0.01% | -41.7% |
| Q2 2022 | $1,273,000 | +46.0% | 21,348 | +120.8% | 0.01% | +33.3% |
| Q3 2021 | $872,000 | +294.6% | 9,670 | +317.4% | 0.01% | +350.0% |
| Q2 2021 | $221,000 | -20.8% | 2,317 | -64.6% | 0.00% | -71.4% |
| Q4 2019 | $279,000 | -68.4% | 6,545 | -52.9% | 0.01% | -77.4% |
| Q2 2019 | $883,000 | -28.0% | 13,900 | -21.5% | 0.03% | -27.9% |
| Q1 2019 | $1,227,000 | -16.0% | 17,700 | -47.3% | 0.04% | -23.2% |
| Q4 2018 | $1,460,000 | -47.2% | 33,607 | -7.2% | 0.06% | -54.5% |
| Q3 2018 | $2,763,000 | +35.2% | 36,200 | -9.6% | 0.12% | -19.6% |
| Q1 2018 | $2,043,000 | +592.5% | 40,050 | +823.4% | 0.15% | +410.0% |
| Q1 2017 | $295,000 | – | 4,337 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| First Light Asset Management, LLC | 213,887 | $29,608,000 | 2.19% |
| Rock Springs Capital Management LP | 566,500 | $78,421,000 | 1.66% |
| FEDERATED HERMES, INC. | 4,280,528 | $592,554,000 | 1.21% |
| AtonRa Partners | 17,646 | $2,443,000 | 1.20% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 218,390 | $30,232,000 | 1.05% |
| EMERALD ADVISERS, LLC | 226,875 | $31,406,000 | 1.04% |
| Atika Capital Management LLC | 89,000 | $12,319,000 | 0.96% |
| Capital Impact Advisors, LLC | 25,582 | $3,541,000 | 0.87% |
| JGP Global Gestao de Recursos Ltda. | 1,586 | $220,000 | 0.83% |
| CAPITAL INTERNATIONAL LTD /CA/ | 79,742 | $11,039,000 | 0.64% |